Recent

% | $
Quotes you view appear here for quick access.

Supernus Pharmaceuticals, Inc. (SUPN) Message Board

  • jimfromsavannah jimfromsavannah Oct 19, 2012 3:39 PM Flag

    Why SPN-804 will save lives

    SPN-804 (extended-release oxcarbazepine)

    Our second late-stage product candidate, SPN-804, is a novel, oral, once-daily, extended-release formulation of oxcarbazepine. We submitted an NDA to the FDA for SPN-804 in 2011.
    •SPN-804 delivers oxcarbazepine, another effective antiepileptic drug, which is marketed by Novartis Pharmaceuticals Corporation under the brand name Trileptal®◦Oxcarbazepine is an active voltage-dependent sodium channel blocker that, despite its effectiveness in treating epilepsy, is associated with many side effects that tend to limit its use, such as dizziness, double vision, somnolence, nausea, and vomiting

    •Extended-release, once-daily SPN-804 has been designed to improve patient compliance and to avoid blood level fluctuations that can be associated with many of the side effects or breakthrough seizures that patients can suffer from when taking immediate-release products

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SUPN
19.15+0.37(+1.97%)May 27 4:00 PMEDT